Selling a vacation cabin after decades of summers can feel like a clean financial win, but a hidden federal mechanism waits in the background to collect its share two years after the closing table…
NVIDIA just delivered its loudest quarter of the AI era, yet shares sit nearly 30% below their peak while B200 systems vanish from shelves faster than they ship. The bull case for a run…
Most heirs who inherit a large traditional IRA focus on minimizing each year's required distribution, never realizing that strategy quietly builds a tax balloon set to burst in year 10 at the worst possible…
SpaceX is pouring billions into AI while renting out its data centers to rivals, yet its models trail the competition and its consumer apps barely register. Something does not add up.
Five Nasdaq stocks share the same ex-dividend deadline this week, but they are not all worth buying for the same reason, and at least one comes with a warning flag that most income investors…
Tesla just posted record deliveries while its operating income collapsed and free cash flow went negative, yet BYD keeps selling more electrified vehicles than any company on earth. Which bet actually wins the next…
While seasoned hedge fund managers were quietly offloading their Microsoft shares, Bill Ackman made one of his biggest bets in years going the opposite direction, and he funded it by selling a stock that…
SpaceX just posted one of the most impressive earnings reports in recent memory, and the stock is getting crushed anyway. Two converging forces are threatening to swamp even the strongest bull case, and one…
AMD just posted a record quarter and the stock is tanking anyway, while NVIDIA is surging on a surprise deal that doubles as a direct shot at AMD's biggest ambitions.
A paid-off home and a few thousand dollars in overdue property taxes should not be a catastrophic combination, but in Illinois they could cost a retiree every dollar of equity she spent decades building.
UnitedHealth crushed Q2 estimates and doubled its buyback, yet the stock has pulled back since the report. Whether that dip signals a buying opportunity or a warning sign depends on one number management cannot…
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the…
Seth Klarman spent four decades building a reputation for buying almost nothing, so when Baupost quietly planted a nine-figure flag in a payment network last quarter, the choice of which rail he picked over…
Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may not be what defines the company a decade from now. A billion-dollar bet on…
SpaceX delivered a blockbuster revenue beat in its first public earnings report, yet shares are cratering while every other space stock barely flinches. What spooked investors has nothing to do with rockets and everything…
